5 interventions graded Animal-proven.
17-Alpha-Estradiol
A fascinating mechanistic tool that keeps working in the ITP, but with zero human data and a hard male-only sex bias, it is a research compound, not a supplement anyone should be taking. Interesting biology, not a therapy.
Acarbose
Genuinely impressive and reproducible in male mice, which is why the ITP takes it seriously, but the sex bias is a red flag and there is zero human longevity evidence. A reasonable, cheap, low-risk bet, not a proven human intervention.
Rapamycin (Sirolimus)
The best-validated geroprotector in animals and the most credible pharmaceutical bet, but the human evidence is still thin: one small underpowered RCT that missed its primary endpoints. 'Proven to extend human lifespan' is false. 'Most promising, still unproven, needs the hard trials' is the honest read.
Senolytics: Dasatinib + Quercetin (D+Q)
The senescent-cell-clearance concept is real and D+Q genuinely reduces senescent-cell burden in humans, which is a landmark. But translating that into hard clinical benefit has so far mostly failed or underwhelmed, and dasatinib's toxicity makes self-experimentation reckless. Promising mechanism, unproven therapy.
Taurine
Exploded from one 2023 Science paper into a viral 'anti-aging amino acid,' then the central biomarker claim (taurine declines with age) failed to replicate in a rigorous 2025 study. Cheap and safe, but the human longevity case is now genuinely in doubt. A vivid lesson in not building a supplement trend on a single unreplicated finding.